Clinical Trial Update: Gemox as First and Second Line Therapy in Unknown Primary Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Gemox (gemcitabine plus oxaliplatin) as first- and second-line therapy for unknown primary neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unknown Primary Neoplasms

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Unknown Primary Neoplasms | Phase 2 | Status: COMPLETED